We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WASHINGTON — Patients with inflammatory arthritis who ...
MedPage Today on MSN
Medicare coverage appears spotty for newer rheumatoid arthritis meds
Advantage plans do a better job than standalone Part D policies, albeit with important gap ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Among targeted therapies, patients with VEXAS syndrome ...
People with lower interleukin-6 activity have a reduced risk of cardiovascular diseases, a new LMU study reveals. Lowering the activity of interleukin-6 (IL-6) - a key immune signal regulating ...
Use of conventional synthetic drugs to treat juvenile idiopathic arthritis (JIA) fell by half during 2000-2022, as targeted therapies became increasingly popular, analysis of commercial insurance ...
As IL-6 inhibition comes into practice for PMR, research advances on other therapeutic mechanisms of action, from IL-17 to ...
Guselkumab and risankizumab demonstrated the highest adjusted survival time for effectiveness (RMST, 1.93 years for both; 95% CI, 1.91-1.95 and 1.90-1.96 years, respectively). Risankizumab showed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results